PDB ID: 6WXC
Hetero Atom Contents
The number of atoms exceeds 100,000. So, it can not be displayed here.
Select unit:
Select hetatm:
Select chain: Sequence
Data format:
Color scheme of protein:
| Code | Name | Style | Show | Link | |
|---|---|---|---|---|---|
| CMU | 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl) uracil | PoSSuM | |||
| EDO | 1,2-ethanediol | PoSSuM | |||
| FMT | Formic acid | PoSSuM | |||
| PO4 | Phosphate ion | PoSSuM |
| Code | Name | Show |
|---|
| Code | Name | Emphasize |
|---|
| Code | Name | Show |
|---|
Download interaction data: 6WXC
Structure summary
| Code : | 6WXC PDBj RCSB PDB PDBe | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Header : | VIRAL PROTEIN | ||||||||||||
| Title : | Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with potential repurposing drug Tipiracil | ||||||||||||
| Release Data : | 2020-05-20 | ||||||||||||
| Compound : |
|
||||||||||||
| Source : |
|
||||||||||||
| Authors : | Kim, Y., Maltseva, N., Jedrzejczak, R., Welk, L., Endres, M., Chang, C., Michalska, K., Joachimiak, A., Center for Structural Genomics of Infectious Diseases (CSGID) | ||||||||||||
| Keywords : | SARS Corona virus 2, endoribonuclease, refurbishing drug, COVID-19, Structural Genomics, Center for Structural Genomics of Infectious Diseases, CSGID, VIRAL PROTEIN | ||||||||||||
| Exp. method : | X-RAY DIFFRACTION ( 1.85 Å ) | ||||||||||||
| Citation : |
Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2.
Kim, Y.,Wower, J.,Maltseva, N.
et al.
PubMed: 33564093 Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2
Kim, Y.,Wower, J.,Maltseva, N.
et al.
|
||||||||||||
Reaction
| Chain : | A, B | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UniProt : | P0DTD1 (R1AB_SARS2) | |||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||


